Sino Biopharmaceutical Limited (01244.HK) released its interim financial results, with a net loss attributable to shareholders of 89.35 million yuan, a decrease of 13.68% year-on-year.

The Zhixun Finance APP reports that Sino Biopharmaceutical Limited (01244.HK) has released its interim performance for the six months ending on June 30, 2025. The group achieved a revenue of 209 million yuan, an increase of 1.33% compared to the same period last year; the company's net loss attributable to owners decreased by 89.35 million yuan, a decrease of 13.68% compared to the same period last year; and the basic loss per share was 0.36 yuan.